苏黄止咳胶囊联合孟鲁司特治疗稳定期慢性阻塞性肺疾病的效果  

Effect of Suhuang Zhike Capsules combined with Montelukast in the treatment of patients with stable chronic obstructive pulmonary disease

作　　者：程德忠 杜文峰[1] 吴园明 CHENG Dezhong;DU Wenfeng;WU Yuanming(Department of Respiratory and Critical Care Medicine,Puren Hospital Affiliated to Wuhan University of Science and Technology,Hubei Province,Wuhan430080,China)

机构地区：[1]武汉科技大学附属普仁医院呼吸与危重症医学科

出　　处：《中国医药导报》2020年第4期163-166,170,共5页China Medical Herald

基　　金：湖北省卫生和计划生育委员会科研项目（MJ2017Y065）

摘　　要：目的研究苏黄止咳胶囊联合孟鲁司特治疗稳定期慢性阻塞性肺疾病(COPD)的效果。方法选择2017年6月~2019年1月在武汉科技大学附属普仁医院治疗的稳定期COPD患者146例作为观察对象。按随机数字表法将患者分为观察组和对照组,各73例。两组均给予常规治疗,对照组在此基础上给予孟鲁司特,观察组则在对照组的基础上给予苏黄止咳胶囊,两组均治疗3个月。比较两组疗效、圣乔治呼吸问卷(SGRQ)评分、肺功能、炎性因子,以及药物不良反应。结果观察组总有效率高于对照组(P<0.05)。治疗后两组SGRQ症状评分、疾病影响评分、活动能力评分及总分均较治疗前明显降低,且观察组低于对照组(P<0.05)。治疗后两组第1秒用力呼气量(FEV1)、FEV1/用力肺活量(FEV1/FVC)、最大通气量(MVV)及残气量/肺总量(RV/TLC)均较治疗前明显升高,且观察组明显高于对照组(P<0.05)。治疗后两组C反应蛋白(CRP)、白细胞介素(IL)-17、IL-8和肿瘤坏死因子-α(TNF-α)水平均较治疗前明显降低,且观察组低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论苏黄止咳胶囊联合孟鲁司特治疗稳定期COPD患者效果显著,且能明显改善患者的肺功能及炎性因子水平,安全性较好,值得推广。Objective To study the effect of Suhuang Zhike Capsules combined with Montelukast in the treatment of patients with stable chronic obstructive pulmonary disease(COPD).Methods From June 2017 to January 2019,146 patients with stable COPD treated in Puren Hospital Affiliated to Wuhan University of Science and Technology were recorded as observation objects.The patients were divided into observation group and control group according to random number table method,with 73 cases in each group.The two groups were treated with routine treatment,on basis of which,the patients in the control group were treated with Montelukast,and the observation group was treated with Suhuang Zhike Capsules on basis of the control group.The two groups were treated for 3 months,and the efficacy,St george′s respiratory questionnaire(SGRQ)scores,pulmonary function,inflammatory factors and adverse reactions of the drugs were compared between the two groups.Results The total effective rate of the observation group was significantly higher than that of the control group(P<0.05).After treatment,the SGRQ scores in the two groups were significantly lower than those before treatment,and the observation group was significantly lower than that of the control group(P<0.05).After treatment,the forced expiratory volume in the first second(FEV1),FEV1/maximal vital capacity(FEV1/FVC),maximal ventilation volume(MVV)and residual volume/total lung volume(RV/TLC)in the two groups were significantly higher than those before treatment,which of the observation group were significantly higher than the control group(P<0.05).After treatment,C-reactive protein(CRP),interleukin(IL)-17,IL-8 and tumor necrosis factor-α(TNF-α)in the two groups were significantly lower than those before treatment,which of the observation group were significantly lower than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Suhuang Zhike Capsules combined with Montelukast is effective in the trea

关 键 词：苏黄止咳胶囊 孟鲁司特 稳定期慢性阻塞性肺疾病 疗效 肺功能 炎性因子 

分 类 号：R563[医药卫生—呼吸系统]